Research development

China makes new progress in COVID-19 vaccine research and development

Scientists in a lab developing COVID-19 vaccines. /APC

Scientists in a lab developing COVID-19 vaccines. /APC

China has made new progress in research and development (R&D) of COVID-19 vaccines with multiple technological innovations, the vaccine research team with the Joint Disease Prevention and Control Mechanism said on Wednesday. State Council (JPCMSC).

The country has three inactivated monovalent vaccines against Omicron variants that are in sequential clinical trials in mainland China and the Hong Kong Special Administrative Region, the research team said. The three vaccines are also being tested in the United Arab Emirates, they said, adding that the trials were all going well so far.

Faced with the complex epidemic situation, experts from JPCMSC said that vaccination remains an effective measure of active immunization.

Nine multivalent vaccines against COVID-19 variants have entered clinical trials in China, including some in phase III clinical trials. The country is also actively deploying and promoting R&D of broad-spectrum COVID-19 vaccines.

In addition, an adenoviral vector vaccine for inhalation and a recombinant protein vaccine have also been approved recently. Both can be used for emergency sequential booster vaccination in specific populations six months after receiving two doses of inactivated vaccines.

So far, China has a total of 46 COVID-19 vaccines that have entered clinical trials, and 21 vaccines have been approved for phase III clinical trials overseas.

In addition, nine China-made COVID-19 vaccines, including an inactivated vaccine, an adenoviral vector vaccine and a recombinant protein vaccine, have been approved for market or emergency use with conditions, and three vaccines are on the World Health Organization emergency use list. .